BRIEF-Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027

Reuters03-02 22:15

March 2 (Reuters) - EyePoint Inc EYPT.O:

EYEPOINT ANNOUNCES FIRST PATIENTS DOSED IN BOTH GLOBAL PHASE 3 CLINICAL TRIALS OF DURAVYU™ FOR THE TREATMENT OF DIABETIC MACULAR EDEMA
EYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027
EYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027

Source text: ID:nGNXc3YhH2

Further company coverage: EYPT.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616587443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616587443","market":"us","top_or_hot":-1,"title":"BRIEF-Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027</title></head><body><p><span>March 2 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Inc <span>EYPT.O</span>:</p><ul><li><p>EYEPOINT ANNOUNCES FIRST PATIENTS DOSED IN BOTH GLOBAL PHASE 3 CLINICAL TRIALS OF DURAVYU™ FOR THE TREATMENT OF DIABETIC MACULAR EDEMA</p></li><li><p>EYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027</p></li><li><p>EYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027</p></li></ul><p>Source text: <span>ID:nGNXc3YhH2</span></p><p>Further company coverage: <span>EYPT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-02 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027</title></head><body><p><span>March 2 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Inc <span>EYPT.O</span>:</p><ul><li><p>EYEPOINT ANNOUNCES FIRST PATIENTS DOSED IN BOTH GLOBAL PHASE 3 CLINICAL TRIALS OF DURAVYU™ FOR THE TREATMENT OF DIABETIC MACULAR EDEMA</p></li><li><p>EYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027</p></li><li><p>EYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027</p></li></ul><p>Source text: <span>ID:nGNXc3YhH2</span></p><p>Further company coverage: <span>EYPT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA7SJNZ3:1","article_id":"2616587443","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616587443","pubTimestamp":1772460943,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027March 2 (Reuters) - EyePoint Inc EYPT.O:EYEPOINT ANNOUNCES FIRST PATIENTS DOSED IN BOTH GLOBAL PHASE 3 CLINICAL TRIALS OF DURAV","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","EYPT":"EyePoint","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4007":"制药"},"translate_title":"简介-Eyepoint Inc预计2027年下半年DME Duravyu的营收数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":0.9},"content_text":"BRIEF-Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027March 2 (Reuters) - EyePoint Inc EYPT.O:EYEPOINT ANNOUNCES FIRST PATIENTS DOSED IN BOTH GLOBAL PHASE 3 CLINICAL TRIALS OF DURAVYU™ FOR THE TREATMENT OF DIABETIC MACULAR EDEMAEYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027EYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027Source text: ID:nGNXc3YhH2Further company coverage: EYPT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616587443","isCrawlerRequest":true}